COVID-19 future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{COVID-19}} | {{COVID-19}} | ||
{{CMG | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 8: | Line 8: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
=== Immune Targets === | |||
* The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine. | |||
* Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine. <br /> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 13:38, 16 March 2020
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of COVID-19 future or investigational therapies |
|
Risk calculators and risk factors for COVID-19 future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Immune Targets
- The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine.
- Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine.